

18. The method of claim 15 wherein the chlorotoxin label is detected by enzyme-linked immunosorbent assay.

RECEIVED

JAN 12 2001

TECH CENTER 1600/2900

19. The method of claim 15 wherein the chlorotoxin label is a radiolabel.

20. The method of claim 19 wherein the radiolabel is selected from the group consisting of  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{186}\text{Re}$ ,  $^{131}\text{I}$  and  $^{125}\text{I}$ .

21. The method of any one of claims 19 or 20 wherein the radiolabel is detected by positron emission tomography scanning.

22. The method of claim 15 wherein the chlorotoxin label is a fluorescent moiety.

23. The method of claim 22 wherein the fluorescent moiety is detected from the group consisting of fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow.

24. The method according to claim 22 wherein the fluorescent moiety is detected by a method selected from the group consisting of fluorescent microscopy and fluorescent activated cell sorting.

25. The method of claim 15 wherein the chlorotoxin label is biotin.

26. The method of claim 25 further comprising the step of contacting the sample with avidin to form avidin-biotin-labeled chlorotoxin complexes.

27. The method of claim 26 further comprising the step of contacting the avidin-biotin-labeled chlorotoxin complexes with 3,3'-diaminobenzidine to form a colormetric product wherein the level of the colormetric product is indicative of the level of chlorotoxin binding.

28. The method of claim 15 wherein the tissue sample is frozen.

29. The method of claim 15 wherein the tissue sample is embedded in paraffin.

30. The method of any one of claims 28 or 29 wherein the tissue sample is counterstained.

31. The method of claim 30 wherein the counterstain is selected from the group consisting of methyl green, hematoxylin and eosin.--

#### REMARKS

The Office Action dated May 4, 2000 has been carefully reviewed and the forgoing amendments are made in response thereto. In view of these amendments and the following remarks, Applicants respectfully request reconsideration and reexamination of this application and the timely allowance of the pending claims.

Applicants respectfully submit that no prohibited new matter has been introduced by the amendments. While written description support for the amended claims can be found throughout the specification, specific support for these claims can be found as indicated in the following chart.

Claim No.	Support in Specification
15	page 37, line 18 through page 38, line 4; original claim 7
16	page 12, lines 2-4
17	page 28, lines 6-10